33 results on '"Theodoropoulou S"'
Search Results
2. Democracy with foresight: the key to a socially sustainable transition in Europe (and beyond)
- Author
-
Countouris, N., Piasna, A., Theodoropoulou, S., Azmanova, Albena, Nicolaidis, Kalypso, Countouris, N., Piasna, A., Theodoropoulou, S., Azmanova, Albena, and Nicolaidis, Kalypso
- Abstract
How can the European Union steer a course towards long-term social and ecological well-being in a context of incessant emergencies? Two decades of perpetual crisis management have greatly eroded Europe’s capacity to pursue a sustainable future, as considerations of short-term expediency continue to hamper the four transitions that are necessary – green, digital, geopolitical and socio-economic. At the same time, however, few polities in the world are better suited to the design and promotion of long-term policies. This editorial draws on its authors’ respective research into progressive social transformation and sustainable European integration to identify a path for the socially sustainable transition which we now need and which the rest of this issue of Benchmarking Working Europe further explores.
- Published
- 2023
3. Study of Xbal and Pvull polymorphisms of estrogen receptor alpha (ERα) gene in girls with precocious/early puberty
- Author
-
Theodoropoulou, S. Papadopoulou, A. Karapanou, O. Priftis, K. Papaevangelou, V. Papadimitriou, A.
- Abstract
Purpose: Studies examining association of estrogen receptor alpha (ERα) polymorphisms with early puberty are scarce and results are controversial; data in Caucasian girls are lacking. Main objective was to determine association of Xbal and Pvull polymorphisms of ERα gene in Greek girls with precocious/early puberty Methods: We studied 107 girls with idiopathic precocious/early puberty and 81 young women with pubertal maturation within normal age (controls). Pubertal stage, height SDS (HSDS), and BMI z-score were determined in patients. In controls, height was measured and menarcheal age was self-reported. All participants in the study were genotyped for XbaI and PvuII polymorphisms of the ERα gene. Results: There was no significant difference in XbaI and PvuII polymorphisms between patients and controls. Homozygous, xx and pp, girls had an earlier onset of puberty, although non-significant, than heterozygous or with no polymorphisms p = 0.9; in girls with pubertal onset
- Published
- 2021
4. Serous macular detachment due to nasally located optic disc pit-coloboma
- Author
-
Theodoropoulou, S. Theodossiadis, G. Sallam, A. Theodossiadis, P.
- Published
- 2018
5. Interleukin 33/ST2 signaling regulates inflammatory response in choroidal stroma and ocular angiogenesis: implications for age-related macular degeneration
- Author
-
Theodoropoulou, S., primary, Doyle, S., additional, Copland, D., additional, Liu, J., additional, Wu, J., additional, Campbell, M., additional, and Dick, A., additional
- Published
- 2015
- Full Text
- View/download PDF
6. Interleukin 33/ ST2 signaling regulates inflammatory response in choroidal stroma and ocular angiogenesis: implications for age-related macular degeneration.
- Author
-
Theodoropoulou, S., Doyle, S., Copland, D., Liu, J., Wu, J., Campbell, M., and Dick, A.
- Subjects
- *
RETINAL degeneration , *BLINDNESS , *INTERLEUKIN-33 - Abstract
Purpose Age-related macular degeneration (AMD) is a leading cause of irreversible blindness. We wished to elaborate mechanisms that regulate RPE-choroidal microenvironment in AMD. We hypothesize that retinal pigment epithelial cells (RPE) produce interleukin 33 (IL-33) and regulate choroidal stromal fibroblasts and mast cell activation and angiogenesis in an ST2-dependent manner. Through such mechanisms, change in choroidal architecture may contribute to AMD phenotypes observed clinically. Methods Upon treatment, RPE cells, human choroidal fibroblasts and bone-marrow-derived mast cells (BMMC) were assayed by RT- PCR, Western Blot and ELISA. Choroidal sprouting assay and laser-induced choroidal neovascularization (CNV) were used as models of ocular angiogenesis. Results TLR-stimulation of RPE significantly up-regulated IL-33 expression. ST2+ BMMC generated a spectrum of inflammatory cytokines when cultured with IL-33 rich RPE supernatant. Pretreatment with IL-33 antagonist markedly inhibited the ability of BMMC to produce inflammatory mediators. Importantly, activation of inflammatory cascade upon RPE supernatant treatment was abrogated in ST2-/- BMMC. In a wound-healing assay, recombinant IL-33 treatment of human choroidal fibroblasts impaired their ability to migrate and contract collagen gel. Furthermore, IL-33 treatment promoted vascular choroidal sprouting in WT and IL33-/- explants. CNV was also regulated by exogenous and endogenous IL-33 in WT and IL33-/- mice respectively. Conclusions Our data illuminate an endogenous IL-33/ ST2 pathway between RPE function and choroidal stroma, influencing tissue remodeling and regulating angiogenesis. Our findings support IL-33/ ST2 axis as a therapeutic target in AMD. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Replenishing IRAK-M expression in retinal pigment epithelium attenuates outer retinal degeneration.
- Author
-
Liu J, Copland DA, Clare AJ, Gorski M, Richards BT, Scott L, Theodoropoulou S, Greferath U, Cox K, Shi G, Bell OH, Ou K, Powell JLB, Wu J, Robles LM, Li Y, Nicholson LB, Coffey PJ, Fletcher EL, Guymer R, Radeke MJ, Heid IM, Hageman GS, Chan YK, and Dick AD
- Subjects
- Animals, Humans, Male, Mice, Cellular Senescence, Macular Degeneration metabolism, Macular Degeneration pathology, Macular Degeneration genetics, Mice, Inbred C57BL, Mitochondria metabolism, Interleukin-1 Receptor-Associated Kinases metabolism, Interleukin-1 Receptor-Associated Kinases genetics, Mice, Knockout, Oxidative Stress, Retinal Degeneration metabolism, Retinal Degeneration pathology, Retinal Degeneration genetics, Retinal Pigment Epithelium metabolism, Retinal Pigment Epithelium pathology
- Abstract
Chronic inflammation is a constitutive component of many age-related diseases, including age-related macular degeneration (AMD). Here, we identified interleukin-1 receptor-associated kinase M (IRAK-M) as a key immunoregulator in retinal pigment epithelium (RPE) that declines during the aging process. Rare genetic variants of IRAK3 , which encodes IRAK-M, were associated with an increased likelihood of developing AMD. In human samples and mouse models, IRAK-M abundance in the RPE declined with advancing age or exposure to oxidative stress and was further reduced in AMD. Irak3 -knockout mice exhibited an increased incidence of outer retinal degeneration at earlier ages, which was further exacerbated by oxidative stressors. The absence of IRAK-M led to a disruption in RPE cell homeostasis, characterized by compromised mitochondrial function, cellular senescence, and aberrant cytokine production. IRAK-M overexpression protected RPE cells against oxidative or immune stressors. Subretinal delivery of adeno-associated virus (AAV)-expressing human IRAK3 rescued light-induced outer retinal degeneration in wild-type mice and attenuated age-related spontaneous retinal degeneration in Irak3 -knockout mice. Our data show that replenishment of IRAK-M in the RPE may redress dysregulated pro-inflammatory processes in AMD, suggesting a potential treatment for retinal degeneration.
- Published
- 2024
- Full Text
- View/download PDF
8. Hybrid Nanoparticles from Random Polyelectrolytes and Carbon Dots.
- Author
-
Theodoropoulou S, Vardaxi A, Kagkoura A, Tagmatarchis N, and Pispas S
- Abstract
The present study concerns the preparation of hybrid nanostructures composed of carbon dots (CDs) synthesized in our lab and a double-hydrophilic poly(2-dimethylaminoethyl methacrylate- co -oligo(ethylene glycol) methyl ether methacrylate) (P(DMAEMA- co -OEGMA)) random co polymer through electrostatic interactions between the negatively charged CDs and the positively charged DMAEMA segments of the co polymer. The synthesis of P(DMAEMA- co -OEGMA) co polymer was conducted through RAFT polymerization. Furthermore, the co polymer was converted into a strong cationic random polyelectrolyte through quaternization of the amine groups of DMAEMA segments with methyl iodide (CH
3 I), and it was subsequently utilized for the complexation with the carbon dots. The molecular, physicochemical, and photophysical characterization of the aqueous solution of the co polymers and their hybrid nanoparticles was conducted using dynamic and electrophoretic light scattering (DLS, ELS) and spectroscopic techniques, such as UV-Vis, fluorescence (FS), and FT-IR spectroscopy. In addition, studies of their aqueous solution using DLS and ELS showed their responsiveness to external stimuli (pH, temperature, ionic strength). Finally, the interaction of selected hybrid nanoparticles with iron (III) ions was confirmed through FS spectroscopy, demonstrating their potential application for heavy metal ions sensing.- Published
- 2024
- Full Text
- View/download PDF
9. Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration.
- Author
-
Jones R, Stratton IM, Scanlon PH, and Theodoropoulou S
- Subjects
- Humans, Angiogenesis Inhibitors therapeutic use, Vascular Endothelial Growth Factor A, Follow-Up Studies, Intravitreal Injections, Visual Acuity, Retrospective Studies, Ranibizumab, Wet Macular Degeneration drug therapy
- Abstract
Background/objectives: Timely assessment and treatment of patients with neovascular AMD (nAMD) are crucial to preservation of vision. Loss to follow up (LTFU) in these patients is a problem but this has not been systematically investigated., Subjects/methods: A retrospective review of electronic medical records of patients with nAMD first treated with anti-VEGF therapy from 1st Jan 2014 to 31st Dec 2018, was conducted in January 2021. Any patient not seen for more than 12 months was classed as no longer attending., Results: Of the 1328 patients who attended between 2014 and 2018, 348 had failed to attend and were eligible for inclusion in this study. Reasons noted for discontinuation of care: discharged by clinician (33.3%), died (20.7%), moved to another unit outside of area (17.5%), stopped attending due to ill-health (13.5%), discharged due to failure to attend (5.6%) and patient choice to no longer attend (4.6%). There were 16 (4.6%) who did not receive any further appointments despite clinician request for follow-up. After 5 years, 50.5% of patients were no longer attending for treatment. Age was a factor in failure to attend, with 7 out of 12 patients aged >100 years no longer being followed up, compared to 1 out of 11 of 50-59 year-olds., Conclusions: When analysing visual outcomes in an AMD service it is important to characterise the patients who are lost to follow up. The outcomes for this group may be avoidably poor and understanding the factors influencing LTFU rate is crucial to addressing shortcomings in a hospital AMD service., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
10. Correction to: Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration.
- Author
-
Jones R, Stratton IM, Scanlon PH, and Theodoropoulou S
- Published
- 2023
- Full Text
- View/download PDF
11. Replenishing Age-Related Decline of IRAK-M Expression in Retinal Pigment Epithelium Attenuates Outer Retinal Degeneration.
- Author
-
Liu J, Copland DA, Clare AJ, Gorski M, Richards BT, Scott L, Theodoropoulou S, Greferath U, Cox K, Bell OH, Ou K, Powell JLB, Wu J, Robles LM, Li Y, Nicholson LB, Coffey PJ, Fletcher EL, Guymer R, Radeke MJ, Heid IM, Hageman GS, Chan YK, and Dick AD
- Abstract
Unchecked, chronic inflammation is a constitutive component of age-related diseases, including age-related macular degeneration (AMD). Here we identified interleukin-1 receptor-associated kinase (IRAK)-M as a key immunoregulator in retinal pigment epithelium (RPE) that declines with age. Rare genetic variants of IRAK-M increased the likelihood of AMD. IRAK-M expression in RPE declined with age or oxidative stress and was further reduced in AMD. IRAK-M-deficient mice exhibited increased incidence of outer retinal degeneration at earlier ages, which was further exacerbated by oxidative stressors. The absence of IRAK-M disrupted RPE cell homeostasis, including compromised mitochondrial function, cellular senescence, and aberrant cytokine production. IRAK-M overexpression protected RPE cells against oxidative or immune stressors. Subretinal delivery of AAV-expressing IRAK-M rescued light-induced outer retinal degeneration in wild-type mice and attenuated age-related spontaneous retinal degeneration in IRAK-M-deficient mice. Our data support that replenishment of IRAK-M expression may redress dysregulated pro-inflammatory processes in AMD, thereby treating degeneration., Competing Interests: Competing interests ADD, JL and YKC are named inventors on an International Patent Application No: PCT/EP2022/082518. ADD is consultant for Hubble Tx, Affibody, 4 DMT, Novartis, Roche, UCB, Amilera, Janssen, and ActivBio. RG is consultant for Roche, Genentech, Apellis, Novartis, and Bayer.
- Published
- 2023
- Full Text
- View/download PDF
12. Developing decision support tools incorporating personalised predictions of likely visual benefit versus harm for cataract surgery: research programme
- Author
-
Sparrow JM, Grzeda M, Frost A, Liu C, Johnston RL, Scanlon P, Pithara C, Elliott D, Donovan J, Joseph-Williams N, Holland-Hart D, Donachie PHJ, Dixon P, Kandiyali R, Taylor H, Breheny K, Sterne J, Hollingworth W, Evans D, Fox F, Theodoropoulou S, Hughes R, Quinn M, Gray D, Benjamin L, Loose A, Edwards L, Craggs P, Paget F, Kapoor K, and Searle J
- Abstract
Background: Surgery for established cataract is highly cost-effective and uncontroversial, yet uncertainty remains for individuals about when to proceed and when to delay surgery during the earlier stages of cataract., Objective: We aimed to improve decision-making for cataract surgery through the development of evidence-based clinical tools that provide general information and personalised risk/benefit information., Design: We used a mixed methodology consisting of four work packages. Work package 1 involved the development and psychometric validation of a brief, patient self-reported measure of visual difficulty from cataract and its relief from surgery, named Cataract Patient-Reported Outcome Measure, five items (Cat-PROM5). Work package 2 involved the review and refinement of risk models for adverse surgical events (posterior capsule rupture and visual acuity loss related to cataract surgery). Work package 3 involved the development of prediction models for the Cat-PROM5-based self-reported outcomes from a cohort study of 1500 patients; assessment of the validity of preference-based health economic indices for cataract surgery and the calibration of these to Cat-PROM5; assessment of patients’ and health-care professionals’ views on risk–benefit presentation formats, the perceived usefulness of Cat-PROM5, the value of personalised risk–benefit information, high-value information items and shared decision-making; development of cataract decision aid frequently asked questions, incorporation of personalised estimates of risks and benefits; and development of a cataract decision quality measure to assess the quality of decision-making. Work package 4 involved a mixed-methods feasibility study for a fully powered randomised controlled trial of the use of the cataract decision aid and a qualitative study of discordant or mismatching perceptions of outcome between patients and health-care professionals., Setting: Four English NHS recruitment centres were involved: Bristol (lead centre), Brighton, Gloucestershire and Torbay. Multicentre NHS cataract surgery data were obtained from the National Ophthalmology Database., Participants: Work package 1 – participants ( n = 822) were from all four centres. Work package 2 – electronic medical record data were taken from the National Ophthalmology Database (final set > 1M operations). Work package 3 – cohort study participants were from Bristol ( n = 1200) and Gloucestershire ( n = 300); qualitative and development work was undertaken with patients and health-care professionals from all four centres. Work package 4 – Bristol, Brighton and Torbay participated in the recruitment of patients ( n = 42) for the feasibility trial and recruitment of health-care professionals for the qualitative elements., Interventions: For the feasibility trial, the intervention was the use of the cataract decision aid, incorporating frequently asked questions and personalised estimations of both adverse outcomes and self-reported benefit., Main Outcome Measures: There was a range of quantitative and qualitative outcome measures: questionnaire psychometric performance metrics, risk indicators of adverse surgical events and visual outcome, predictors of self-reported outcome following cataract surgery, patient and health-care practitioner views, health economic calibration measures and randomised controlled trial feasibility measures., Data Sources: The data sources were patient self-reported questionnaire responses, study clinical data collection forms, recorded interviews with patients and health-care professionals, and anonymised National Ophthalmology Database data., Results: Work package 1 – Cat-PROM5 was developed and validated with excellent to good psychometric properties (Rasch reliability 0.9, intraclass correlation repeatability 0.9, unidimensionality with residual eigenvalues ≤ 1.5) and excellent responsiveness to surgical intervention (Cohen delta –1.45). Work package 2 – earlier risk models for posterior capsule rupture and visual acuity loss were broadly affirmed ( C -statistic for posterior capsule rupture 0.64; visual acuity loss 0.71). Work package 3 – the Cat-PROM5-based self-reported outcome regression models were derived based on 1181 participants with complete data ( R
2 ≈ 30% for each). Of the four preference-based health economic indices assessed, two demonstrated reasonable performance. Cat-PROM5 was successfully calibrated to health economic indices; adjusted limited dependent variable mixture models offered good to excellent fit (root-mean-square error 0.10–0.16). The personalised quantitative risk information was generally perceived as beneficial. A cataract decision aid and cataract decision quality measure were successfully developed based on the views of patients and health-care professionals. Work package 4 – data completeness was good for the feasibility study primary and secondary variables both before and after intervention/surgery (data completeness range 100–88%). Considering ability to recruit, the sample size required, instrumentation and availability of necessary health economic data, a fully powered randomised controlled trial (patients, n = 800, effect size 0.2 standard deviations, power 80%; p = 0.05) of the cataract decision aid would be feasible following psychometric refinement of the primary outcome (the cataract decision quality measure). The cataract decision aid was generally well-received by patients and health-care professionals, with cautions raised regarding perceived time and workload barriers. Discordant outcomes mostly related to patient dissatisfaction, with no clinical problem found., Limitations: The National Ophthalmology Database data are expected to include some errors (mitigated by large multicentre data aggregations). The feasibility randomised controlled trial primary outcome (the cataract decision quality measure) displayed psychometric imperfections requiring refinement. The clinical occurrence of discordant outcomes is uncommon and the study team experienced difficulty identifying patients in this situation., Future Work: Future work could include regular review of the risk models for adverse outcomes to ensure currency, and the technical precision of complex-numbers analysis of refractive outcome to invite opportunities to improve post-operative spectacle-free vision. In addition, a fully powered randomised controlled trial of the cataract decision aid would be feasible, following psychometric refinement of the primary outcome (the cataract decision quality measure); this would clarify its potential role in routine service delivery., Conclusions: In this research programme, evidence-based clinical tools have been successfully developed to improve pre-operative decision-making in cataract surgery. These include a psychometrically robust, patient-reported outcome measure (Cat-PROM5); prediction models for patient self-reported outcomes using Cat-PROM5; prediction models for clinically adverse surgical events and adverse visual acuity outcomes; and a cataract decision aid with relevant general information and personalised risk/benefit predictions. In addition, the successful mapping of Cat-PROM5 to existing health economic indices was achieved and the performances of indices were assessed in patients undergoing cataract surgery. A future full-powered randomised controlled trial of the cataract decision aid would be feasible (patients, n = 800, effect size 0.2 standard deviations, power 80%; p = 0.05)., Trial Registration: This trial is registered as ISRCTN11309852., Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research ; Vol. 10, No. 9. See the NIHR Journals Library website for further project information., (Copyright © 2022 Sparrow et al. This work was produced by Sparrow et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.)- Published
- 2022
- Full Text
- View/download PDF
13. Unravelling the therapeutic potential of IL-33 for atrophic AMD.
- Author
-
Clare AJ, Liu J, Copland DA, Theodoropoulou S, and Dick AD
- Subjects
- Aged, Angiogenesis Inhibitors, Cytokines metabolism, Humans, Interleukin-33 metabolism, Retinal Pigment Epithelium pathology, Vascular Endothelial Growth Factor A metabolism, Visual Acuity, Geographic Atrophy pathology, Wet Macular Degeneration drug therapy, Wet Macular Degeneration metabolism
- Abstract
Age-related macular degeneration (AMD), a degenerative disease affecting the retinal pigment epithelium (RPE) and photoreceptors in the macula, is the leading cause of central blindness in the elderly. AMD progresses to advanced stages of the disease, atrophic AMD (aAMD), or in 15% of cases "wet" or neovascular AMD (nAMD), associated with substantial vision loss. Whilst there has been advancement in therapies treating nAMD, to date, there are no licenced effective treatments for the 85% affected by aAMD, with disease managed by changes to diet, vitamin supplements, and regular monitoring. AMD has a complex pathogenesis, involving highly integrated and common age-related disease pathways, including dysregulated complement/inflammation, impaired autophagy, and oxidative stress. The intricacy of AMD pathogenesis makes therapeutic development challenging and identifying a target that combats the converging disease pathways is essential to provide a globally effective treatment. Interleukin-33 is a cytokine, classically known for the proinflammatory role it plays in allergic disease. Recent evidence across degenerative and inflammatory disease conditions reveals a diverse immune-modulatory role for IL-33, with promising therapeutic potential. Here, we will review IL-33 function in disease and discuss the future potential for this homeostatic cytokine in treating AMD., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
14. Study of Xbal and Pvull polymorphisms of estrogen receptor alpha (ERα) gene in girls with precocious/early puberty.
- Author
-
Theodoropoulou S, Papadopoulou A, Karapanou O, Priftis K, Papaevangelou V, and Papadimitriou A
- Subjects
- Child, Female, Genotype, Greece, Humans, Polymorphism, Genetic, Estrogen Receptor alpha genetics, Puberty, Precocious genetics
- Abstract
Purpose: Studies examining association of estrogen receptor alpha (ERα) polymorphisms with early puberty are scarce and results are controversial; data in Caucasian girls are lacking. Main objective was to determine association of Xbal and Pvull polymorphisms of ERα gene in Greek girls with precocious/early puberty METHODS: We studied 107 girls with idiopathic precocious/early puberty and 81 young women with pubertal maturation within normal age (controls). Pubertal stage, height SDS (HSDS), and BMI z-score were determined in patients. In controls, height was measured and menarcheal age was self-reported. All participants in the study were genotyped for XbaI and PvuII polymorphisms of the ERα gene., Results: There was no significant difference in XbaI and PvuII polymorphisms between patients and controls. Homozygous, xx and pp, girls had an earlier onset of puberty, although non-significant, than heterozygous or with no polymorphisms p = 0.9; in girls with pubertal onset <7 years, the association tended to become significant, p = 0.09. Girls with xxpp genotype were significantly taller, HSDS 1.63, p = 0.014. In controls, homozygosity for Xbal (xx) and PvuII (pp) was associated with significantly earlier menarche than in women with no polymorphism, p = 0.013 and p = 0.026, respectively, and xxpp genotype was associated with taller adult height, p = 0.017., Conclusion: XbaI and PvuII polymorphisms are not related to idiopathic precocious/early puberty. Early pubertal girls homozygous for both polymorphisms presented earlier onset of puberty, although statistically non-significant, and taller height than girls heterozygous or without these polymorphisms. Homozygosity for both polymorphisms is associated with earlier menarche and taller adult height.
- Published
- 2021
- Full Text
- View/download PDF
15. Interleukin-33 regulates metabolic reprogramming of the retinal pigment epithelium in response to immune stressors.
- Author
-
Scott LM, Vincent EE, Hudson N, Neal C, Jones N, Lavelle EC, Campbell M, Halestrap AP, Dick AD, and Theodoropoulou S
- Subjects
- Animals, Cell Line, Cell Proliferation, Cell Survival, Energy Metabolism, Gene Knockdown Techniques, Glycolysis drug effects, Humans, Hydrogen Peroxide pharmacology, Interferon Inducers pharmacology, Interleukin-33 drug effects, Interleukin-33 genetics, Lipopolysaccharides pharmacology, Mice, Mice, Knockout, Mitochondria drug effects, Oxidants pharmacology, Oxidation-Reduction drug effects, Oxidative Stress, Poly I-C pharmacology, Primary Cell Culture, Pyruvic Acid metabolism, Cell Respiration physiology, Glycolysis physiology, Interleukin-33 metabolism, Mitochondria metabolism, Retinal Pigment Epithelium metabolism
- Abstract
It remains unresolved how retinal pigment epithelial cell metabolism is regulated following immune activation to maintain retinal homeostasis and retinal function. We exposed retinal pigment epithelium (RPE) to several stress signals, particularly Toll-like receptor stimulation, and uncovered an ability of RPE to adapt their metabolic preference on aerobic glycolysis or oxidative glucose metabolism in response to different immune stimuli. We have identified interleukin-33 (IL-33) as a key metabolic checkpoint that antagonizes the Warburg effect to ensure the functional stability of the RPE. The identification of IL-33 as a key regulator of mitochondrial metabolism suggests roles for the cytokine that go beyond its extracellular "alarmin" activities. IL-33 exerts control over mitochondrial respiration in RPE by facilitating oxidative pyruvate catabolism. We have also revealed that in the absence of IL-33, mitochondrial function declined and resultant bioenergetic switching was aligned with altered mitochondrial morphology. Our data not only shed new light on the molecular pathway of activation of mitochondrial respiration in RPE in response to immune stressors but also uncover a potentially novel role of nuclear intrinsic IL-33 as a metabolic checkpoint regulator.
- Published
- 2021
- Full Text
- View/download PDF
16. Treatment with interleukin-33 is non-toxic and protects retinal pigment epithelium in an ageing model of outer retinal degeneration.
- Author
-
Clare AJ, Copland DA, Nicholson LB, Liu J, Neal CR, Moss S, Dick AD, and Theodoropoulou S
- Subjects
- Animals, Disease Models, Animal, Humans, Immunohistochemistry, Macular Degeneration etiology, Macular Degeneration metabolism, Macular Degeneration pathology, Mice, Mice, Knockout, Retinal Degeneration drug therapy, Retinal Degeneration pathology, Retinal Pigment Epithelium pathology, Retinal Pigment Epithelium ultrastructure, Treatment Outcome, Aging genetics, Aging metabolism, Interleukin-33 pharmacology, Retinal Degeneration etiology, Retinal Degeneration metabolism, Retinal Pigment Epithelium drug effects, Retinal Pigment Epithelium metabolism
- Abstract
The leading cause of central vision loss, age-related macular degeneration (AMD), is a degenerative disorder characterized by atrophy of retinal pigment epithelium (RPE) and photoreceptors. For 15% of cases, neovascularization occurs, leading to acute vision loss if left untreated. For the remaining patients, there are currently no treatment options and preventing progressive RPE atrophy remains the main therapeutic goal. Previously, we have shown treatment with interleukin-33 can reduce choroidal neovascularization and attenuate tissue remodelling. Here, we investigate IL-33 delivery in aged, high-fat diet (HFD) fed mice on a wildtype and complement factor H heterozygous knockout background. We characterize the non-toxic effect following intravitreal injection of IL-33 and further demonstrate protective effects against RPE cell death with evidence of maintaining metabolic retinal homeostasis of Cfh+/-~HFD mice. Our results further support the potential utility of IL-33 to prevent AMD progression., (© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
17. Treatment of diabetic retinopathy through neuropeptide Y-mediated enhancement of neurovascular microenvironment.
- Author
-
Ou K, Copland DA, Theodoropoulou S, Mertsch S, Li Y, Liu J, Schrader S, Liu L, and Dick AD
- Subjects
- Animals, Apoptosis drug effects, Cellular Microenvironment drug effects, Diabetes Mellitus, Experimental drug therapy, Diabetes Mellitus, Experimental genetics, Diabetes Mellitus, Experimental pathology, Diabetic Retinopathy genetics, Diabetic Retinopathy pathology, Endothelial Cells drug effects, Humans, Mice, N-Methylaspartate pharmacology, Neuropeptide Y genetics, Rats, Retina drug effects, Retina pathology, Retinal Ganglion Cells drug effects, Retinal Ganglion Cells pathology, Retinal Neovascularization genetics, Retinal Neovascularization pathology, Vascular Endothelial Growth Factor A pharmacology, Diabetic Retinopathy drug therapy, N-Methylaspartate genetics, Neuropeptide Y pharmacology, Retinal Neovascularization drug therapy, Vascular Endothelial Growth Factor A genetics
- Abstract
Diabetic retinopathy (DR) is one of the most severe clinical manifestations of diabetes mellitus and a major cause of blindness. DR is principally a microvascular disease, although the pathogenesis also involves metabolic reactive intermediates which induce neuronal and glial activation resulting in disruption of the neurovascular unit and regulation of the microvasculature. However, the impact of neural/glial activation in DR remains controversial, notwithstanding our understanding as to when neural/glial activation occurs in the course of disease. The objective of this study was to determine a potential protective role of neuropeptide Y (NPY) using an established model of DR permissive to N-methyl-D-aspartate (NMDA)-induced excitotoxic apoptosis of retinal ganglion cells (RGC) and vascular endothelial growth factor (VEGF)-induced vascular leakage. In vitro evaluation using primary retinal endothelial cells demonstrates that NPY promotes vascular integrity, demonstrated by maintained tight junction protein expression and reduced permeability in response to VEGF treatment. Furthermore, ex vivo assessment of retinal tissue explants shows that NPY can protect RGC from excitotoxic-induced apoptosis. In vivo clinical imaging and ex vivo tissue analysis in the diabetic model permitted assessment of NPY treatment in relation to neural and endothelial changes. The neuroprotective effects of NPY were confirmed by attenuating NMDA-induced retinal neural apoptosis and able to maintain inner retinal vascular integrity. These findings could have important clinical implications and offer novel therapeutic approaches for the treatment in the early stages of DR., (© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
18. Corrigendum to "Restoring retinal neurovascular health via substance P" [Exp. Cell Res. (2019)].
- Author
-
Ou K, Mertsch S, Theodoropoulou S, Wu J, Liu J, Copland DA, Schrader S, Liu L, and Dick AD
- Published
- 2019
- Full Text
- View/download PDF
19. Dysregulated claudin-5 cycling in the inner retina causes retinal pigment epithelial cell atrophy.
- Author
-
Hudson N, Celkova L, Hopkins A, Greene C, Storti F, Ozaki E, Fahey E, Theodoropoulou S, Kenna PF, Humphries MM, Curtis AM, Demmons E, Browne A, Liddie S, Lawrence MS, Grimm C, Cahill MT, Humphries P, Doyle SL, and Campbell M
- Subjects
- Animals, Blood-Retinal Barrier diagnostic imaging, Blood-Retinal Barrier drug effects, Capillary Permeability drug effects, Capillary Permeability physiology, Chlorocebus aethiops, Claudin-5 genetics, Diet, High-Fat adverse effects, Disease Models, Animal, Fluorescein Angiography, Fundus Oculi, Gene Knockdown Techniques, Geographic Atrophy drug therapy, Geographic Atrophy etiology, Geographic Atrophy prevention & control, Healthy Volunteers, Humans, Magnetic Resonance Imaging, Mice, Mice, Transgenic, Photoperiod, RNA, Small Interfering metabolism, Retinal Pigment Epithelium drug effects, Retinal Pigment Epithelium pathology, ARNTL Transcription Factors metabolism, Blood-Retinal Barrier pathology, Circadian Clocks physiology, Claudin-5 metabolism, Geographic Atrophy pathology
- Abstract
Age-related macular degeneration (AMD) is the leading cause of central retinal vision loss worldwide, with an estimated 1 in 10 people over the age of 55 showing early signs of the condition. There are currently no forms of therapy available for the end stage of dry AMD, geographic atrophy (GA). Here, we show that the inner blood-retina barrier (iBRB) is highly dynamic and may play a contributory role in GA development. We have discovered that the gene CLDN5, which encodes claudin-5, a tight junction protein abundantly expressed at the iBRB, is regulated by BMAL1 and the circadian clock. Persistent suppression of claudin-5 expression in mice exposed to a cholesterol-enriched diet induced striking retinal pigment epithelium (RPE) cell atrophy, and persistent targeted suppression of claudin-5 in the macular region of nonhuman primates induced RPE cell atrophy. Moreover, fundus fluorescein angiography in human and nonhuman primate subjects showed increased retinal vascular permeability in the evening compared with the morning. These findings implicate an inner retina-derived component in the early pathophysiological changes observed in AMD, and we suggest that restoring the integrity of the iBRB may represent a novel therapeutic target for the prevention and treatment of GA secondary to dry AMD.
- Published
- 2019
- Full Text
- View/download PDF
20. Restoring retinal neurovascular health via substance P.
- Author
-
Ou K, Mertsch S, Theodoropoulou S, Wu J, Liu J, Copland DA, Schrader S, Liu L, and Dick AD
- Subjects
- Animals, Apoptosis drug effects, Blood-Retinal Barrier drug effects, Blood-Retinal Barrier metabolism, Cells, Cultured, Mice, Mice, Inbred C57BL, N-Methylaspartate administration & dosage, N-Methylaspartate pharmacology, Rats, Rats, Wistar, Retina drug effects, Retina metabolism, Vascular Endothelial Growth Factors metabolism, Retinal Neovascularization metabolism, Substance P metabolism
- Abstract
Regulation of vascular permeability plays a major role in the pathophysiology of visually threatening conditions such as retinal vein occlusion and diabetic retinopathy. Principally, several factors such as vascular endothelial growth factor (VEGF), are up-regulated or induced in response to hypoxia thus adversely affecting the blood-retinal barrier (BRB), resulting in retinal edema and neovascularisation. Furthermore, current evidence supports a dysregulation of the inner retinal neural-vascular integrity as a critical factor driving retinal ganglion cell (RGC) death and visual loss. The principal objective of this study was to interrogate whether Substance P (SP), a constitutive neurotransmitter of amacrine and ganglion cells, may protect against N-methyl-d-aspartate (NMDA)-induced excitotoxic apoptosis of ganglion cells and VEGF-induced vessel leakage in the retina. Tight junctional protein expression and a Vascular Permeability Image Assay were used to determine vascular integrity in vitro. The protective effect of SP on RGC was established in ex vivo retinal explants and in vivo murine models. After NMDA administration, a reduction in TUNEL+ cells and a maintained number of Brn-3a+ cells were found, indicating an inhibition of RGC apoptosis mediated by SP. Additionally, SP maintained endothelial tight junctions and decreased VEGF-induced vascular permeability. In conclusion, administration of SP protects against NMDA apoptosis of RGC and VEGF-induced endothelial barrier breakdown., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
21. [Lipids and mental disorders: Evidence, uncertainties and perspectives].
- Author
-
Theodoropoulou S and Gialouris AG
- Subjects
- Fatty Acids, Omega-3 metabolism, Humans, Lipid Metabolism, Mental Disorders metabolism
- Abstract
Brain is an organ with the highest lipid concentration in the body. Cellular membrane lipids can affect both the positioning and the functioning of membrane proteins, thus regulating several cell actions. Changes in the lipid composition of cell membrane can modulate the microenvironment and consequently the function of its proteins, e.g. neurotransmission. Some of the first studies on the subject have shown a negative correlation between serum cholesterol levels and depression, suicidality and behavioral disorders. Several studies -but not all- have found decreased concentrations of ω-3 polyunsaturated fatty acids (ω-3-PUFA) in plasma or erythrocyte membranes of patients with depression, bipolar disorder or after a suicide attempt. In some cases, positive results after their administration have been reported. The effect of ω-3-PUFA in affective disorders is attributed to their action on neurotransmission, neuroplasticity as well as to their anti-inflammatory and anti-oxidative properties. Besides, decreased levels of ω-3-PUFA have been found in erythrocytes or platelets of schizophrenic patients. Some studies have shown in schizophrenics an increased rate of membrane phospholipids breakdown and a decreased ratio of ω-3-PUFA incorporation in phospholipids, possibly because of increased activity of phospholipase A2, an enzyme with crucial role in signaling transduction. Deficient dietetic ingestion of ω-3-PUFA may increase the risk for development of schizophrenia, while a diet rich in ω-3-PUFA may have a preventive role for the disease or improve its course. Although there is no evidence for their action as a monotherapy, they may be useful as an add-on therapy to drug treatment. Some authors suggest that abnormal sphingolipid metabolism, leading to accumulation of ceramides, may be responsible for the development of mood and anxiety disorders, as well as for induction of inflammation or oxidative stress, mechanisms possibly responsible for the physical symptoms of depression. Some drugs seem to combine inhibition of sphingomyelinase (an enzyme catalyzing the production of ceramides) and antidepressant effect. Despite the multitude of related studies, many aspects of the subject remain obscure. Current research focuses on the validity of preventive (especially in the perinatal period) or therapeutic administration of ω-3-PUFA as well as to the pharmacological manipulation of enzymes involved in lipid metabolism (e.g. sphingomyelinase) for the treatment of psychiatric disorders.
- Published
- 2019
- Full Text
- View/download PDF
22. Clinical pathophysiology of thyroid eye disease: The Cone Model.
- Author
-
Meyer P, Das T, Ghadiri N, Murthy R, and Theodoropoulou S
- Subjects
- Adipose Tissue pathology, Eye Movements physiology, Graves Ophthalmopathy diagnostic imaging, Humans, Magnetic Resonance Imaging, Ocular Motility Disorders physiopathology, Oculomotor Muscles diagnostic imaging, Orbit pathology, Tomography, X-Ray Computed, Graves Ophthalmopathy physiopathology, Models, Biological, Oculomotor Muscles pathology
- Abstract
The clinical features of thyroid eye disease are dictated by the orbit's compartmentalisation; particularly, the muscle cone, which is delimited by the rectus muscles, their inter-muscular septa and the posterior sclera. The cone is anchored to the orbit apex and contains the posterior globe, the muscle bellies, a fat pad, and the blood circulation, optic nerve, and CSF sheath. It is surrounded by mobile extraconal fat, retained by the orbital septum.Thyroid eye disease is caused by expansion of muscle bellies and fat within the cone. Mechanical properties of the cone determine that the disease partitions into three phases: circumferential expansion, with forward displacement of extraconal fat; axial elongation, with increasing cone pressure; impedance of posterior venous outflow, with cone oedema and venous flow reversal.Venous flow reversal can be observed in the conjunctival circulation. It is initially transient, accompanying rises in cone pressure caused by eye movements, but later becomes permanent. It is a useful clinical sign that locates diseased muscles and anticipates venous compressive crises.Strabismus arises when inflamed rectus muscles, swollen by hydrated glycosaminoglycans, lose contractility and compliance. The incomitance is moderated by increasing stiffness affecting all the rectus muscles, as they are stretched during cone expansion.Immunomodulation, which rapidly reduces cone volume, relieving muscle elongation and stiffness, may paradoxically unmask strabismus. However, ciclosporin A suppresses late post-inflammatory fibrosis and only 4 of 71 patients so-treated required strabismus surgery.The cone model also accounts for the variety of clinical presentations of thyroid eye disease.
- Published
- 2019
- Full Text
- View/download PDF
23. Müller Cells Stabilize Microvasculature through Hypoxic Preconditioning.
- Author
-
Ou K, Mertsch S, Theodoropoulou S, Wu J, Liu J, Copland DA, Scott LM, Dick AD, Schrader S, and Liu L
- Subjects
- Angiopoietin-Like Protein 4 analysis, Cell Line, Cell Proliferation drug effects, Cell Survival drug effects, Culture Media, Conditioned pharmacology, Ependymoglial Cells cytology, Ependymoglial Cells metabolism, Glycolysis drug effects, Humans, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Microvessels metabolism, Mitochondria drug effects, Mitochondria metabolism, Neovascularization, Physiologic drug effects, TOR Serine-Threonine Kinases metabolism, Vascular Endothelial Growth Factor A analysis, Cell Hypoxia
- Abstract
Background/aims: Hypoxia of the retina is a common pathogenic drive leading to vision loss as a result of tissue ischemia, increased vascular permeability and ultimately retinal neovascularisation. Here we tested the hypothesis that Müller cells stabilize the neurovascular unit, microvasculature by suppression of HIF-1α activation as a result of hypoxic preconditioning., Methods: Tube Formation Assay and In vitro Vascular Permeability Image Assay were used to analyze angiogenesis and vascular integrity. Seahorse XF Cell Mito Stress Test was used to measure mitochondrial respiration. Gene and protein expression were examined by qRTPCR, ELISA and western blot., Results: Hypoxic insult induces a significant induction of proangiogenic factors including vascular endothelial growth factor (VEGF) and angiopoietinlike 4 (ANGPTL-4) resulting in angiogenesis and increased vascular permeability of vascular endothelial cells. Hypoxic preconditioning of a human retinal Müller glia cell line significantly attenuates HIF-1α activation through the inhibition of mTOR and concomitant induction of aerobic glycolysis, stabilizing endothelial cells., Conclusion: Hypoxic preconditioning of Müller cells confers a robust protection to endothelial cells, through the suppression of HIF1α activation and its downstream regulation of VEGF and ANGPTL-4., Competing Interests: The authors declare that there is no conflict of interest regarding the publication of this paper., (© Copyright by the Author(s). Published by Cell Physiol Biochem Press.)
- Published
- 2019
- Full Text
- View/download PDF
24. Comment re: Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?
- Author
-
Theodoropoulou S, Theodossiadis GP, Grigoropoulos VG, and Theodossiadis PG
- Subjects
- Eye, Humans, Traction, Vitreous Detachment
- Published
- 2018
- Full Text
- View/download PDF
25. Serous macular detachment due to nasally located optic disc pit-coloboma.
- Author
-
Theodoropoulou S, Theodossiadis G, Sallam A, and Theodossiadis P
- Published
- 2018
- Full Text
- View/download PDF
26. A Perspective of AMD Through the Eyes of Immunology.
- Author
-
Copland DA, Theodoropoulou S, Liu J, and Dick AD
- Subjects
- Animals, Complement Factor H genetics, Humans, Inflammasomes immunology, Immunity, Cellular physiology, Immunity, Innate physiology, Inflammation immunology, Macular Degeneration immunology
- Abstract
Despite strong genetic associations, compelling human histological data and numerous hypotheses generated with supportive animal data, the mechanisms of inflammation or inflammatory control of cell health during progression of age-related macular degeneration arguably remain elusive. This perspective delivers a view that maintaining tissue health requires active immune cellular and tissue pathways, but when responses are perturbed or exaggerated, chronic inflammation is destructive. There are potential pathways and processes to enable understanding and determine how potential causative factors including altered cellular metabolism, senescence, oxidative stress disrupt tissue homeostasis are engaged. Establishing differences in the immune phenotype between normal aging and AMD, and how the inter-relatedness of these triggers contribute to pathobiology is integral for future therapeutic success.
- Published
- 2018
- Full Text
- View/download PDF
27. Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece.
- Author
-
Avgerinou C, Giannezi I, Theodoropoulou S, Lazaris V, Kolliopoulou G, Zikos P, Alamanos Y, Leotsinidis M, and Symeonidis A
- Subjects
- Aged, Aged, 80 and over, Alcohol Drinking, Case-Control Studies, Comorbidity, Environmental Exposure adverse effects, Female, Greece epidemiology, Humans, Male, Middle Aged, Occupational Exposure adverse effects, Odds Ratio, Pesticides adverse effects, Risk Factors, Smoking, Diet, Myelodysplastic Syndromes epidemiology, Myelodysplastic Syndromes etiology, Occupations
- Abstract
Purpose: We have observed an increasing incidence of myelodysplastic syndromes (MDS) in the geographic area of Western Greece during the past two decades. The objective of this study was to investigate potential risk factors for the manifestation of MDS in this area of Greece., Methods: A hospital-based case-control study was conducted in the public hospitals of the region. Participants were interviewed based on a questionnaire regarding demographics, occupational exposures, smoking, alcohol consumption, dietary, and domestic factors., Results: A total of 228 individuals (126 cases, 102 controls) were recruited in this study. Univariate analysis showed that risk of MDS was associated with a family history of hematologic malignancy or solid tumor, exposure to pesticides, insecticides, herbicides, increased weekly intake of meat and eggs, and increased alcohol intake, whereas fruit intake had a protective effect. Analysis by pesticide ingredient showed a weak association of exposure to paraquat and glyphosate with the occurrence of MDS. Multivariate analysis showed that independent risk factors for the manifestation of MDS were family history of solid tumor (OR 2.47, 95% CI 1.32-4.65), meat intake for ≥5 days/week (OR 2.67, 95% CI 1.05-6.80) and exposure to pesticides (OR 3.25, 95% CI 1.73-6.11)., Conclusions: Exposure to pesticides is a major risk factor of MDS in Western Greece. Family history of solid tumor and increased meat intake also appear to play a role in the pathogenesis of MDS. Public health authorities should implement policies to advise and protect farmers from the harmful effects of agrochemicals. Emphasis should also be given to health promotion advice including healthy eating.
- Published
- 2017
- Full Text
- View/download PDF
28. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.
- Author
-
Theodoropoulou S, Ellabban AA, Johnston RL, Cilliers H, Mohamed Q, and Sallam AB
- Subjects
- Aged, 80 and over, Dose-Response Relationship, Drug, Drug Implants, Drug Therapy, Combination, Female, Follow-Up Studies, Glaucoma drug therapy, Glucocorticoids, Humans, Intraocular Pressure, Intravitreal Injections, Macular Edema diagnosis, Macular Edema etiology, Male, Ocular Hypertension drug therapy, Retinal Vein Occlusion diagnosis, Retinal Vein Occlusion drug therapy, Retrospective Studies, Time Factors, Tomography, Optical Coherence, Treatment Outcome, Antihypertensive Agents therapeutic use, Dexamethasone administration & dosage, Glaucoma complications, Macular Edema drug therapy, Ocular Hypertension complications, Retinal Vein Occlusion complications, Visual Acuity
- Abstract
Purpose: To report the short-term safety of dexamethasone implants to treat macular edema due to retinal vein occlusion (RVO), in eyes with treated glaucoma or ocular hypertension at baseline using an as-needed re-treatment regimen., Methods: Retrospective clinical database study from two centers using the same electronic medical record system. Extracted data included: intraocular pressure (IOP), visual acuity (VA), central 1 mm retinal thickness (CRT) by optical coherence tomography, phakic status, number of injections, glaucoma treatment, and peri-operative complications., Results: Thirty-three eyes of 33 patients on IOP-lowering treatment for glaucoma or ocular hypertension (OHT) at baseline and mean IOP of 16 mmHg at baseline received one to four (mean, 1.8; median, 1) dexamethasone implants over 18 months for RVO-related macular edema. Fourteen eyes (42 %) had IOP of ≥21 mmHg, and three eyes (9 %) had IOP of ≥35 mmHg at one or more visits during the study period. Nine of 14 eyes (64 %) with raised IOP required additional topical treatment only for a mean (SE) period of 8.5 months (3.2), while the remaining five eyes (36 %) required long-term additional IOP-lowering treatment for a mean (SE) of 16 months (1.44). Surgery for IOP lowering was not required in any eye. Mean VA (SE) improved from 44 (3) ETDRS letters at baseline to 47 letters (5) at 2 months (p = 0.049), 48 (8) letters at 6 months and 46 (4) letters at 12 months. Mean CRT (SE) improved from 530 (25) μm at baseline to 323 (27) μm at 2 months (p < 0.001), 498 (76) μm at 6 months, and 359 (25) μm at 12 months (p < 0.001)., Conclusion: The short-term IOP rise after intravitreal dexamethasone implant in eyes with glaucoma or ocular hypertension at baseline was acceptable and consistent with previous reports in patients without preexisting glaucoma. Treated OHT or glaucoma may not be a strict contraindication against the use of dexamethasone implant, but close monitoring of IOP is required.
- Published
- 2017
- Full Text
- View/download PDF
29. Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye.
- Author
-
Theodoropoulou S, Copland DA, Liu J, Wu J, Gardner PJ, Ozaki E, Doyle SL, Campbell M, and Dick AD
- Subjects
- Adolescent, Adult, Aged, Animals, Cells, Cultured, Choroid immunology, Choroidal Neovascularization drug therapy, Choroidal Neovascularization immunology, Fibroblasts immunology, Humans, Interleukin-1 Receptor-Like 1 Protein metabolism, Interleukin-33 therapeutic use, Mice, Inbred C57BL, Mice, Knockout, Middle Aged, Recombinant Proteins therapeutic use, Retinal Pigment Epithelium immunology, Young Adult, Interleukin-33 immunology, Macular Degeneration immunology
- Abstract
Age-related macular degeneration (AMD) is the leading cause of central vision loss worldwide. Loss of retinal pigment epithelium (RPE) is a major pathological hallmark in AMD with or without pathological neovascularization. Although activation of the immune system is implicated in disease progression, pathological pathways remain diverse and unclear. Here, we report an unexpected protective role of a pro-inflammatory cytokine, interleukin-33 (IL-33), in ocular angiogenesis. IL-33 and its receptor (ST2) are expressed constitutively in human and murine retina and choroid. When RPE was activated, IL-33 expression was markedly elevated in vitro. We found that IL-33 regulated tissue remodelling by attenuating wound-healing responses, including reduction in the migration of choroidal fibroblasts and retinal microvascular endothelial cells, and inhibition of collagen gel contraction. In vivo, local administration of recombinant IL-33 inhibited murine choroidal neovascularization (CNV) formation, a surrogate of human neovascular AMD, and this effect was ST2-dependent. Collectively, these data demonstrate IL-33 as a potential immunotherapy and distinguishes pathways for subverting AMD pathology. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland., (© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.)
- Published
- 2017
- Full Text
- View/download PDF
30. Optical Coherence Tomography Angiography Findings in Dengue-Related Maculopathy: A Case Report.
- Author
-
Tavassoli S, Carreño E, Teoh SC, Theodoropoulou S, Bailey C, Lee RW, and Dick AD
- Subjects
- Adult, Female, Fluorescein Angiography, Humans, Scotoma etiology, Tomography, Optical Coherence methods, Dengue complications, Retinal Diseases etiology
- Abstract
The ophthalmic manifestations of dengue fever include a visually impairing maculopathy, where patients are left with a central or paracentral relative scotoma. The authors present a case of a 26-year-old female patient returning from Thailand with unilateral reduction in visual acuity and a central scotoma associated with dengue fever. The authors report the use of the optical coherence tomography angiography (OCTA) as a noninvasive imaging platform to demonstrate its value in showing the persistent changes corresponding to the functional central scotoma in dengue-related maculopathy, which often cannot be visualized clinically or by standard OCT and fundus fluorescein angiography. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:1057-1060.]., (Copyright 2016, SLACK Incorporated.)
- Published
- 2016
- Full Text
- View/download PDF
31. Impairing autophagy in retinal pigment epithelium leads to inflammasome activation and enhanced macrophage-mediated angiogenesis.
- Author
-
Liu J, Copland DA, Theodoropoulou S, Chiu HA, Barba MD, Mak KW, Mack M, Nicholson LB, and Dick AD
- Subjects
- Animals, Autophagy, Caspase 3 metabolism, Cells, Cultured, Coculture Techniques, Macular Degeneration pathology, Mice, Retinal Pigment Epithelium immunology, Rotenone pharmacology, Choroidal Neovascularization immunology, Inflammasomes metabolism, Macrophages cytology, Macular Degeneration immunology, Retinal Pigment Epithelium cytology
- Abstract
Age-related decreases in autophagy contribute to the progression of age-related macular degeneration (AMD). We have now studied the interaction between autophagy impaired in retinal pigment epithelium (RPE) and the responses of macrophages. We find that dying RPE cells can activate the macrophage inflammasome and promote angiogenesis. In vitro, inhibiting rotenone-induced autophagy in RPE cells elicits caspase-3 mediated cell death. Co-culture of damaged RPE with macrophages leads to the secretion of IL-1β, IL-6 and nitrite oxide. Exogenous IL-6 protects the dysfunctional RPE but IL-1β causes enhanced cell death. Furthermore, IL-1β toxicity is more pronounced in dysfunctional RPE cells showing reduced IRAK3 gene expression. Co-culture of macrophages with damaged RPE also elicits elevated levels of pro-angiogenic proteins that promote ex vivo choroidal vessel sprouting. In vivo, impaired autophagy in the eye promotes photoreceptor and RPE degeneration and recruitment of inflammasome-activated macrophages. The degenerative tissue environment drives an enhanced pro-angiogenic response, demonstrated by increased size of laser-induced choroidal neovascularization (CNV) lesions. The contribution of macrophages was confirmed by depletion of CCR2(+) monocytes, which attenuates CNV in the presence of RPE degeneration. Our results suggest that the interplay between perturbed RPE homeostasis and activated macrophages influences key features of AMD development.
- Published
- 2016
- Full Text
- View/download PDF
32. Role of interleukin 33/ST2 axis in the immune-mediated pathogenesis of age-related macular degeneration.
- Author
-
Theodoropoulou S, Copland DA, Liu J, and Dick AD
- Abstract
Background: Age-related macular degeneration is a leading cause of irreversible blindness. Altered immune responses drive degeneration, in response to oxidative stress and hypoxia-induced regulation of metabolism. We tested the hypothesis that toll-like receptor activation of retinal pigment epithelium and cellular metabolic switch upregulate interleukin 33, which acts through its receptor ST2 to activate both choroidal stromal fibroblasts and mast cells. By such mechanisms, the fibrosis and insidious degeneration, which we observe clinically, is accentuated., Methods: Retinal pigment epithelial cells (ARPE-19 and B6-RPE07) were stimulated with toll-like receptor ligands, and energetic pathways were assessed through lactate production and the expression of glycolytic enzymes. Expression profile and secretion of interleukin 33 were determined by RT-PCR and western blots. Function and expression profile of bone-marrow-derived mast cells and human choroidal fibroblasts were also assessed., Findings: The production of lactate, determining aerobic glycolysis, increased after stimulation of retinal pigment epithelial cells with LPS or poly(I:C), indicating an increase in the glycolytic activity after toll-like receptor stimulation. Increased levels of GLUT1 transcripts, and upregulation of GAPDH expression corroborated this finding. Furthermore, increased expression of interleukin 33 was dependent on a glycolytic metabolic switch and was enhanced under hypoxic conditions. ST2 was highly expressed in retinal pigment epithelium, choroidal mast cells, and choroidal fibroblasts in mouse and man. ST2+ bone-marrow-derived mast cells generated a spectrum of inflammatory cytokines and PGS2 when cultured with interleukin-33-rich retinal pigment epithelium supernatant. Interleukin-33 treatment impaired fibroblast migration and gel contraction alongside suppression of MMP-2 and MMP-9 expression., Interpretation: Our data highlight an unrecognised link between retinal pigment epithelium bioenergetic status and tissue remodelling of choroidal stroma. Our findings suggest that the interleukin 33/ST2 axis and changing bioenergetic sources are potential therapeutic targets to inhibit progression of age-related macular degeneration., Funding: National Institute for Health Research, National Eye Research Centre., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
33. Effects of metformin on retinoblastoma growth in vitro and in vivo.
- Author
-
Brodowska K, Theodoropoulou S, Meyer Zu Hörste M, Paschalis EI, Takeuchi K, Scott G, Ramsey DJ, Kiernan E, Hoang M, Cichy J, Miller JW, Gragoudas ES, and Vavvas DG
- Subjects
- AMP-Activated Protein Kinases biosynthesis, Animals, Apoptosis drug effects, Autophagy drug effects, Gene Expression Regulation, Neoplastic drug effects, Humans, Mice, Retinoblastoma genetics, Retinoblastoma pathology, TOR Serine-Threonine Kinases biosynthesis, Xenograft Model Antitumor Assays, Cell Proliferation drug effects, Metformin administration & dosage, Retinoblastoma drug therapy
- Abstract
Recent studies suggest that the anti-diabetic drug metformin may reduce the risk of cancer and have anti-proliferative effects for some but not all cancers. In this study, we examined the effects of metformin on human retinoblastoma cell proliferation in vitro and in vivo. Two different human retinoblastoma cell lines (Y79, WERI) were treated with metformin in vitro and xenografts of Y79 cells were established in nu/nu immune-deficient mice and used to assess the effects of pharmacological levels of metformin in vivo. Metformin inhibited proliferation of the retinoblastoma cells in vitro. Similar to other studies, high concentrations of metformin (mM) blocked the cell cycle in G0‑G1, indicated by a strong decrease of G1 cyclins, especially cyclin D, cyclin-dependent kinases (4 and 6), and flow cytometry assessment of the cell cycle. This was associated with activation of AMPK, inhibition of the mTOR pathways and autophagy marker LC3B. However, metformin failed to suppress growth of xenografted tumors of Y79 human retinoblastoma cells in nu/nu mice, even when treated with a maximally tolerated dose level achieved in human patients. In conclusion, suprapharmacological levels (mM) of metformin, well above those tolerated in vivo, inhibited the proliferation of retinoblastoma cells in vitro. However, physiological levels of metformin, such as seen in the clinical setting, did not affect the growth of retinoblastoma cells in vitro or in vivo. This suggests that the potential beneficial effects of metformin seen in epidemiological studies may be limited to specific tumor types or be related to indirect effects/mechanisms not observed under acute laboratory conditions.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.